Tiantan Biopharma first quarter net profit declines

Beijing Tiantan Biological Products Corp (SSE:600161) announced its first-quarter 2025 results, revealing a 7.84% increase in total operating income, reaching CNY 131,776.64 thousand. Despite the revenue growth, operating profit and total profit decreased by 21.31% and 21.30% respectively. Net profit attributable to shareholders fell by 22.90% to CNY 24,414.57 thousand. Basic earnings per share were CNY 0.12. The company attributed the profit decline to a decrease in product prices offsetting the gains from increased sales volume. The company's total assets stood at CNY 1,623,534.38 thousand at the end of the quarter, with shareholders' equity at CNY 1,138,285.00 thousand, representing a 2.19% increase in net assets per share. The company says it will focus on cost control measures to improve profitability.